Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Merck to Shed 200 Jobs in Japan by 2015
December 3, 2013
- Eisai to Offer Voluntary Retirement Program in Japan
December 3, 2013
- Takeda President Calls GSK Weber Competitive Global Talent, Pushes Globalization
December 2, 2013
- Eisai Files for Approval of Pariet for Preventing Recurrent Ulcers during Aspirin Therapy
December 2, 2013
- GSK Exec Tapped as Takeda’s Next President, 1st Non-Japanese to Lead Japan Juggernaut
December 2, 2013
- AnGes MG to Resume Collategene Development for Critical Limb Ischemia Treatment: President Yamada
November 29, 2013
- No Mortality Cases Reported in Association with Eliquis at PMS: BMKK/Pfizer Japan
November 29, 2013
- MRs, Marketing Division Collaborate to Create Promotional Materials as Part of Pfizer Japan’s New Training Program
November 29, 2013
- President Hasegawa of Takeda Confident About Achieving Targets in Midterm Growth Strategy; Company to Appoint CIO
November 28, 2013
- Teva Japan Pres. Kikushige to Double as Head of Taisho Pharma
November 28, 2013
- Teva Pharma Japan to Temporarily Suspend Supply of Elsamet Combination Tablets
November 28, 2013
- Azilva Tops Physician “Mind Share” Ranking in GP, HP Markets in October: New Survey
November 27, 2013
- Sanofi to Revamp Sales Organization, 5 Units to Come Under Direct Control of President
November 27, 2013
- Santen’s Anti-Allergic Eye Drops Alesion Goes on Sale
November 27, 2013
- Eisai to Take Over Marketing Rights for Gliadel from Nobelpharma
November 27, 2013
- CHMP Recommends Approval of Otsuka’s Delamanid for Treatment of MDR-TB
November 27, 2013
- IFN-Free Hepatitis C Drugs Could Hit Pharmacy Shelves in 2014, New Option for Elderly Patients
November 26, 2013
- Alfresa Pharma Gets Additional Indication for Anafranil
November 26, 2013
- Farmorubicin Approved for Additional Dosage and Administration for Hepatic Cancer: Pfizer Japan
November 26, 2013
- GSK’s Paxil Granted Japan’s 1st PTSD Indication
November 26, 2013
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…